Biological and clinical features of Tγδ LGLL patients according to Vδ2 status
| . | Vδ2+, n/N (%) . | Vδ2−, n/N (%) . | P value . |
|---|---|---|---|
| LGL > 2000/mm3 | 2/17 (11.8) | 9/29 (31.0) | .1723 |
| CD16 expression | 14/14 (100) | 18/22 (81.8) | .1412 |
| CD56 expression | 14/14 (100) | 2/22 (9.1) | <.0001 |
| CD57 expression | 14/14 (100) | 18/22 (81.8) | .1412 |
| KIR expression | 9/14 (64.3) | 3/16 (18.8) | .0236 |
| CD158a expression | 1/14 (7.1) | 1/16 (6.2) | >.9999 |
| CD158b expression | 6/14 (42.9) | 2/16 (12.5) | .1010 |
| CD158e expression | 3/14 (21.4) | 1/16 (6.2) | .3155 |
| CD94 expression | 13/17 (76.5) | 12/28 (42.9) | .0351 |
| NKG2A expression | 10/14 (71.4) | 1/16 (6.2) | .0004 |
| NKG2C expression | 0/14 (0) | 3/16 (18.8) | .2276 |
| Vγ9+ | 17/17 (100) | 6/33 (18.2) | <.0001 |
| STAT3 mutated | 0/17 (0) | 17/34 (50) | .0003 |
| STAT5b mutated | 3/17 (17.6) | 0/34 (0) | .0327 |
| ANC < 1500/mm3 | 1/17 (5.9) | 21/32 (65.6) | <.0001 |
| ANC < 500/mm3 | 0/17 (0) | 10/32 (31.2) | .0094 |
| Hb < 120 g/L | 0/17 (0) | 18/32 (56.2) | <.0001 |
| Hb < 90 g/L | 0/17 (0) | 11/32 (34.4) | .0090 |
| PLTs < 100 000/mm3 | 1/17 (5.9) | 4/32 (12.5) | .6463 |
| Splenomegaly | 0/16 (0) | 8/30 (26.7) | .0371 |
| Autoimmune/inflammatory diseases | 1/16 (6.2) | 15/31 (48.4) | .0039 |
| SPMs | 4/14 (28.6) | 6/24 (25) | >.9999 |
| Need for treatment | 0/14 (0) | 12/22 (54.5) | .0007 |
| . | Vδ2+, n/N (%) . | Vδ2−, n/N (%) . | P value . |
|---|---|---|---|
| LGL > 2000/mm3 | 2/17 (11.8) | 9/29 (31.0) | .1723 |
| CD16 expression | 14/14 (100) | 18/22 (81.8) | .1412 |
| CD56 expression | 14/14 (100) | 2/22 (9.1) | <.0001 |
| CD57 expression | 14/14 (100) | 18/22 (81.8) | .1412 |
| KIR expression | 9/14 (64.3) | 3/16 (18.8) | .0236 |
| CD158a expression | 1/14 (7.1) | 1/16 (6.2) | >.9999 |
| CD158b expression | 6/14 (42.9) | 2/16 (12.5) | .1010 |
| CD158e expression | 3/14 (21.4) | 1/16 (6.2) | .3155 |
| CD94 expression | 13/17 (76.5) | 12/28 (42.9) | .0351 |
| NKG2A expression | 10/14 (71.4) | 1/16 (6.2) | .0004 |
| NKG2C expression | 0/14 (0) | 3/16 (18.8) | .2276 |
| Vγ9+ | 17/17 (100) | 6/33 (18.2) | <.0001 |
| STAT3 mutated | 0/17 (0) | 17/34 (50) | .0003 |
| STAT5b mutated | 3/17 (17.6) | 0/34 (0) | .0327 |
| ANC < 1500/mm3 | 1/17 (5.9) | 21/32 (65.6) | <.0001 |
| ANC < 500/mm3 | 0/17 (0) | 10/32 (31.2) | .0094 |
| Hb < 120 g/L | 0/17 (0) | 18/32 (56.2) | <.0001 |
| Hb < 90 g/L | 0/17 (0) | 11/32 (34.4) | .0090 |
| PLTs < 100 000/mm3 | 1/17 (5.9) | 4/32 (12.5) | .6463 |
| Splenomegaly | 0/16 (0) | 8/30 (26.7) | .0371 |
| Autoimmune/inflammatory diseases | 1/16 (6.2) | 15/31 (48.4) | .0039 |
| SPMs | 4/14 (28.6) | 6/24 (25) | >.9999 |
| Need for treatment | 0/14 (0) | 12/22 (54.5) | .0007 |
P values are calculated using Fisher exact test. Significant P values are reported in bold.